Harvest Fund Management Co. Ltd Buys 860 Shares of Glaukos Co. (NYSE:GKOS)

Harvest Fund Management Co. Ltd raised its stake in Glaukos Co. (NYSE:GKOS) by 2,263.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 898 shares of the medical instruments supplier’s stock after buying an additional 860 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Glaukos were worth $117,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Values First Advisors Inc. acquired a new position in shares of Glaukos in the third quarter worth approximately $25,000. GAMMA Investing LLC increased its position in Glaukos by 68.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after purchasing an additional 486 shares during the period. KBC Group NV raised its holdings in Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after purchasing an additional 201 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in shares of Glaukos in the 2nd quarter worth approximately $187,000. Finally, Procyon Advisors LLC acquired a new position in shares of Glaukos in the 3rd quarter worth approximately $210,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Activity

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $14,198,425.93. The trade was a 2.18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the sale, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. This represents a 8.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on GKOS shares. Stifel Nicolaus increased their price objective on shares of Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Piper Sandler set a $140.00 price target on Glaukos in a report on Thursday, October 17th. BTIG Research boosted their price objective on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. raised their target price on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Wells Fargo & Company lifted their target price on Glaukos from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $135.45.

Glaukos Trading Up 1.4 %

Shares of Glaukos stock opened at $142.68 on Thursday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 52 week low of $59.58 and a 52 week high of $146.86. The stock has a 50 day moving average price of $133.15 and a two-hundred day moving average price of $124.27. The stock has a market capitalization of $7.87 billion, a PE ratio of -47.25 and a beta of 1.02.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. During the same quarter last year, the firm posted ($0.50) EPS. Glaukos’s revenue was up 23.9% compared to the same quarter last year. As a group, equities analysts anticipate that Glaukos Co. will post -1.96 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.